GO
Loading...

Amgen Inc

More

  • Cramer: AmEx great blue chip stock     Wednesday, 30 Jul 2014 | 9:15 AM ET

    CNBC's Jim Cramer breaks down the earnings of American Express and Amgen. And David Faber digs into Sprint's quarterly results and the likelihood of a deal with T-Mobile.

  • *Sanofi to file drug for US and EU approval by year-end. PARIS, July 30- A new drug being developed by French drugmaker Sanofi and U.S. partner Regeneron cut "bad" LDL cholesterol more than placebo and existing treatments in nine late-stage clinical trials, the companies said on Wednesday.

  • Early movers: S, TWTR, AXP, GM, MAR, NFLX & more Wednesday, 30 Jul 2014 | 7:45 AM ET
    Traders work the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • July 29- Amgen Inc on Tuesday said it would cut up to 15 percent of its work force and close plants in a series of moves aimed at reallocating resources as it prepares to introduce new medicines it hopes will drive future growth.

  • After-hours buzz: Twitter, Amgen, AmEx & more Tuesday, 29 Jul 2014 | 5:06 PM ET

    Check out which companies are making headlines after the bell Tuesday: Twitter, Amgen, American Express & more.

  • July 29- Amgen Inc on Tuesday said it would cut up to 15 percent of its global work force and close plants as part of a series of moves aimed at reallocating resources as it prepares for the eventual launch of medicines it hopes will drive future growth.

  • Amgen tops estimate; announces jobs cuts Tuesday, 29 Jul 2014 | 4:40 PM ET
    Amgen offices in Fremont, Calif.

    Amgen posted higher-than-expected profit and said it would cut 12 to 15 percent of its workforce and close two plants.

  • July 29- Amgen Inc on Tuesday posted higher-than-expected second-quarter profit in a rebound from a disappointing first quarter, helped by strong sales of its rheumatoid arthritis drug Enbrel, and it significantly raised its full-year earnings forecast.

  • Why the Fed could raise rates sooner than you think Monday, 28 Jul 2014 | 4:36 PM ET
    Janet Yellen

    The Fed meets for two days, starting Tuesday, and is widely expected to taper back its monthly bond buying program by another $10 billion to $25 billion - and do little else.

  • Summer's busiest week for markets is here Friday, 25 Jul 2014 | 6:10 PM ET
    Traders work on the floor of the New York Stock Exchange (NYSE) on Friday.

    A crush of big cap earnings and arguably the most important economic reports until September make next week the busiest of the summer for markets.

  • Ernst & Young to pay $4 million in SEC settlement Monday, 14 Jul 2014 | 3:40 PM ET
    Ernst and Young signage in New York City.

    Accounting giant Ernst & Young will pay $4 million to settle civil charges that it violated auditor independence rules, U.S. regulators said.

  • In 2012, Ernst& Young voluntarily decided to cease performing lobbying work for SEC registrant audit clients. " "Auditor independence is critical to the integrity of the financial reporting process," said Scott Friestad, an associate director in the SEC's enforcement division.

  • Early movers: APP, MS, LULU, BIND, ABBV & more Thursday, 3 Jul 2014 | 7:52 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • July 2- Drug developer Bind Therapeutics said it ended a partnership with Amgen Inc to develop targeted cancer therapy due to unsatisfactory results.

  • Aging stinks, so at least make some money from it Monday, 23 Jun 2014 | 8:00 AM ET

    The US population is getting grayer, and while getting old stinks, there are plenty of ways to profit from an aging demographic using ETFs.

  • *Shire rejects AbbVie offer valued at 46.26 pounds a share. LONDON, June 20- British drugmaker Shire has rejected a 27 billion-pound takeover offer from AbbVie, the latest attempt by a U.S. healthcare firm to tap into lower tax rates abroad via an acquisition.

  • LONDON, June 20- British drugmaker Shire has rejected a 27 billion-pound takeover offer from AbbVie, the latest attempt by a U.S. healthcare firm to tap into the London- listed group's low tax rate. Abbvie's takeover offer proposed creating a new U.S.-listed holding company with a UK tax domicile in a so-called "inversion" move.

  • *Shire expecting to receive approaches, taps Citi- sources. LONDON, June 17- Shares in Shire hit a record high on Tuesday on expectations of a takeover as dealmaking sweeps the drugs sector, after Reuters reported the group had hired investment bank Citi as a defence adviser. Shire and Citi declined to comment.

  • Shire braces for takeover bids, hires Citi: Sources Monday, 16 Jun 2014 | 2:25 PM ET
    Ten milligram tablets of the hyperactivity drug, Adderall, made by Shire Plc.

    Shire has hired investment bank Citi as an adviser following a wave of deals in the healthcare sector.

  • LONDON, June 16- London- listed drugmaker Shire has hired investment bank Citi as an adviser, expecting to receive takeover approaches following a wave of deals in the healthcare sector, sources familiar with the matter told Reuters.